HS
Therapeutic Areas
Lantheus Holdings Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PYLARIFY (piflufolastat F 18) | Prostate Cancer (Diagnostic Imaging) | Approved/Commercial |
| PYLARIFY AI | Analysis of PYLARIFY PET images | Approved/Commercial |
| Definity | Cardiac Ultrasound Imaging | Approved/Commercial |
| PNT2002 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 3 |
| Pnt2003 | Prostate Cancer (Therapeutic) | Phase 1 |
| LNTH-101 | Solid Tumor Imaging (Pan-Cancer) | Phase 1 |
| 18F-Flurpiridaz | Myocardial Perfusion Imaging | Phase 3 |
| LMI 1195 | Cardiac Neurotransmission Imaging | Preclinical/Phase 1 |
Leadership Team at Lantheus Holdings
MA
Mary Anne Heino
President and Chief Executive Officer, Director
BM
Brian Markison
Chairman of the Board
PB
Paul Blanchfield
Chief Financial Officer
EM
Etienne Montagut
Chief Business Officer
LT
Lizzy Tsu
Chief Legal Officer and Corporate Secretary
VG
Vipin Garg
Chief Technology Officer
CL
Caroline Loew
Chief Scientific Officer
MK
Mark K. Tsuchiyama
Chief Accounting Officer and Corporate Controller
KA
Karen A. Ling
Chief Corporate Affairs Officer
DM
Daniel M. Niedzwiecki
Chief Medical Officer